福建广生堂药业股份有限公司 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 单位：万元 | | | 占用方与上 | 上市公司 | 2025年半年度 | 2025年半年 度占用累计 | 2025年半年 度占用资金 | 2025年半年 | 2025年半年 | 占用形 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 市公司的关联关系 | 核算的会 | 期初占用资金 | 发生金额（不 | 的利息（如 | 度偿还累计 | 度期末占用 | 成原因 | 占用性质 | | | | | 计科目 | 余额 | | | 发生金额 | 资金余额 | | | | | | | | | 含利息） | 有） | | | | | | 控股股东、实际控制人 | | | | | | | | | | 非经营性占用 | | 及其附属企业 | | | | | | | | | | 非经营性占用 | | 小计 | - | - | - | | | | | | | - | | 前控股股东、实际控制 | | ...

证券代码：300436 证券简称：广生堂 公告编号：2025059 福建广生堂药业股份有限公司 关于签署投资意向书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 一、交易概述 为进一步扩充营运资金，保障创新药研发投入，加快推动在研创新药研发进 程，福建广生堂药业股份有限公司（以下简称"公司"）创新药控股子公司福建 广生中霖生物科技有限公司（以下简称"广生中霖"）于 2025 年 8 月 21 日与华 欣石恒科技创业投资基金（青岛）合伙企业（有限合伙）（以下简称"华欣创投"） 及济南汇扬投资合伙企业（有限合伙）（以下简称"汇扬投资"）签署《投资意 向书》，华欣创投、汇扬投资或其指定方以及其与广生中霖共同认可的跟投方拟 按广生中霖本次投资的投前估值不低于人民币 25 亿元，以不超过 2 亿人民币现 1、本次签署的投资意向书系各方就本次交易达成的初步意向，属于各方基 于合作意愿和基本合作原则、方向签署的意向性约定，最终交易协议仍需由交易 各方进一步商谈并另行签订协议确定，能否达成最终交易存在不确定性，请广大 投资者注意投资风险。 2、 根据《深圳 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 福建广生堂药业股份有限公司（以下简称"公司"）于 2025 年 8 月 20 日召 开了第五届董事会第十次会议和第五届监事会第九次会议，审议通过了《关于公 司 2025 年半年度报告的议案》。 为使广大投资者全面了解公司 2025 年半年度的经营成果及财务状况，公司 《2025 年半年度报告》及《2025 年半年度报告摘要》将于 2025 年 8 月 22 日刊 登 在 中 国 证 券 监 督 管 理 委 员 会 指 定 创 业 板 信 息 披 露 网 站 巨 潮 资 讯 网 （www.cninfo.com.cn）上，敬请投资者注意查阅。 特此公告。 福建广生堂药业股份有限公司董事会 2025 年 8 月 21 日 1 证券代码：300436 证券简称：广生堂 公告编号：2025058 福建广生堂药业股份有限公司 关于 2025 年半年度报告披露的提示性公告 ...

证券代码：300436 证券简称：广生堂 公告编号：2025056 福建广生堂药业股份有限公司 关于第五届监事会第九次会议决议的公告 本公司及监事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 表决结果：有效表决票数 3 票，同意 3 票，反对 0 票，弃权 0 票。 具体内容详见公司于 2025 年 8 月 22 日刊登在《证券时报》《中国证券报》 《上海证券报》《证券日报》和巨潮资讯网 www.cninfo.com.cn 的《2025 年半 年度报告摘要》。《2025 年半年度报告》详见巨潮资讯网 www.cninfo.com.cn。 三、备查文件 1、经与会监事签字的第五届监事会第九次会议决议 1 特此公告。 福建广生堂药业股份有限公司（以下简称"公司"）第五届监事会第九次会 议于 2025 年 8 月 10 日以邮件、短信等形式发出通知，于 2025 年 8 月 20 日在福 建省福州市闽侯县福州高新区乌龙江中大道 7 号海西高新技术产业园创新园二 期 16 号楼 13F 会议室以现场结合通讯表决方式召开。会议由监事会主席主持， 会议应出席 ...

证券代码：300436 证券简称：广生堂 公告编号：2025055 福建广生堂药业股份有限公司 关于第五届董事会第十次会议决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 福建广生堂药业股份有限公司（以下简称"公司"）第五届董事会第十次会 议于 2025 年 8 月 10 日以邮件、短信等形式发出通知，于 2025 年 8 月 20 日在福 建省福州市闽侯县福州高新区乌龙江中大道 7 号海西高新技术产业园创新园二 期 16 号楼 12F 会议室以现场结合通讯表决方式召开。会议由董事长李国平先生 主持，会议应出席董事 8 人，实际出席董事 8 人，监事会成员列席了会议。会议 的召开符合《公司法》和《公司章程》的规定。 二、董事会会议审议情况 （一）审议通过《关于公司2025年半年度报告的议案》 经审核，董事会认为公司《2025 年半年度报告》及《2025 年半年度报告摘 要》的编制程序符合法律、行政法规的规定，报告内容真实、准确、完整地反映 了公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 表决结果：有效表决票数8 ...

Financial Performance - The company's operating revenue for the first half of 2025 was ¥208,857,590.44, a decrease of 4.27% compared to ¥218,178,671.51 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was -¥66,688,112.39, representing an 85.05% decline from -¥36,037,775.88 in the previous year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥70,837,753.33, a decrease of 46.97% compared to -¥48,200,090.88 in the same period last year[20]. - The basic earnings per share were -¥0.4187, down 85.02% from -¥0.2263 in the same period last year[20]. - The company reported a net loss of CNY 62,521,477.64 for the first half of 2025, compared to a net loss of CNY 34,191,609.44 in the previous year[168]. - The company's net profit for the current period was -70,407,273.85, compared to -36,120,978.74 in the previous period, indicating a significant increase in losses[169]. - The total comprehensive income for the current period was -70,407,273.85, compared to -36,120,978.74 in the previous period, indicating a worsening financial position[169]. - The company reported a significant increase in income tax expenses by 308.72% to ¥7.89 million, primarily due to profit growth in its subsidiary Jiangsu Zhongxing[70]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,365,155,258.54, a decrease of 5.12% from ¥1,438,807,956.07 at the end of the previous year[20]. - The net assets attributable to shareholders of the listed company were ¥292,735,994.35, down 18.72% from ¥360,178,823.72 at the end of the previous year[20]. - The company's total liabilities decreased slightly to CNY 1,039,539,327.80 from CNY 1,042,030,034.50, a reduction of 0.5%[165]. - The company's total equity at the end of the reporting period was 1,061,854,000 yuan, with a significant portion attributed to retained earnings of 803,190,000 yuan[186]. - The company's cash and cash equivalents decreased significantly to CNY 33,917,555.13 from CNY 95,887,610.78, a decline of 64.7%[163]. - The company's total liabilities were reported at 675,700,000 yuan, which is a critical factor in assessing the company's financial health[186]. Research and Development - The company has invested significantly in innovative drug development since its IPO in 2015, focusing on liver health and antiviral fields, with multiple projects underway[42]. - The innovative drug Tizoxanide, approved in November 2023, shows superior efficacy compared to Paxlovid, significantly reducing clinical recovery time by 2 days[43]. - The innovative drug GST-HG141 has shown over 80% complete response rate in HBV DNA suppression during its II phase clinical trial, indicating strong antiviral effects[45]. - The company has established a comprehensive product pipeline focusing on liver health, including hepatitis B and C treatments, with ongoing development of innovative drugs[65]. - The company plans to invest CNY 200 million in R&D for new product development in the upcoming year, focusing on innovative therapies[181]. - The company is focusing on innovative drug development, with several patents related to its antiviral drug entecavir, which is crucial for treating chronic hepatitis B[60]. Market Position and Strategy - The global pharmaceutical market is expected to reach approximately $2.4 trillion by 2029, with a compound annual growth rate (CAGR) of 5%-8% from 2023 onwards[27]. - The Chinese pharmaceutical market is projected to grow to 2.29 trillion yuan by 2025 and 2.99 trillion yuan by 2030, with an industry growth rate of 7-9% from 2023 to 2025[28]. - The company aims to maintain a dual strategy of internal growth and external expansion to enhance its product pipeline and optimize product structure[29]. - The company is exploring market expansion opportunities in Southeast Asia, targeting a 10% market share within the next two years[181]. - The company plans to enhance its marketing system and implement diversified marketing strategies to boost revenue from existing product lines[58]. - The company is actively exploring diversified financing channels to meet funding needs and reduce financing costs[94]. Risks and Challenges - The management has highlighted potential risks and countermeasures in the report, urging investors to remain aware of investment risks[5]. - The company acknowledges the risk of intensified market competition from both domestic and international pharmaceutical companies[87]. - The company is facing risks related to new drug development, including potential delays in clinical trials and regulatory approvals[89]. - The company has faced continuous operating losses over the past three years due to the transition from generic to innovative drugs and the impact of centralized drug procurement policies[93]. Corporate Governance and Social Responsibility - The company emphasizes the protection of shareholder rights, particularly for minority shareholders, through improved internal management and communication[103]. - The company engaged with investors over 200 times through various channels, ensuring the protection of shareholders' rights[104]. - The company actively participates in social welfare initiatives, focusing on education and charity, and encourages employee involvement in these activities[105]. - The company adheres to environmental protection laws and continuously improves waste management and energy efficiency through new technologies and processes[105]. - The company has made commitments regarding stock reduction and competition avoidance, ensuring compliance with relevant laws and regulations[107]. Shareholder Information - The company has a total of 20,269 shareholders at the end of the reporting period[148]. - Fujian Aohua Group Co., Ltd. holds 17.00% of the shares, with a reduction of 8,000,000 shares during the reporting period[148]. - The company plans to issue A-shares to specific targets in 2025, with the proposal disclosed on April 3, 2025, and accepted by the Shenzhen Stock Exchange on May 23, 2025[140]. - The company has a total of 13 subsidiaries included in the consolidated financial statements, with no changes in the number of subsidiaries compared to the previous period[196].

证券之星消息，8月21日化学制药板块较上一交易日上涨0.09%，*ST苏吴领涨。当日上证指数报收于 3771.1，上涨0.13%。深证成指报收于11919.76，下跌0.06%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 600200 | *ST苏吴 | 0.96 | 5.49% | 43.67万 | | 4141.60万 | | 300705 | 九典制药 | 19.87 | 4.97% | 52.35万 | | 10.35 Z | | 300573 | 兴齐眼药 | 67.48 | 4.69% | 22.77万 | | 15.19 Z | | 688506 | 百利天恒 | 324.96 | 4.21% | 1.62万 | | 5.23亿 | | 002940 | 昂利康 | 51.36 | 3.86% | 15.16万 | | 7.69亿 | | 002020 | 京新药业 | 19.52 | 2.90% | 32.05万 | | 6.16 ...

Market Overview - The A-share market experienced a sudden decline in the afternoon, with the Shanghai Composite Index dropping over 0.2% before recovering slightly, while the Shenzhen Component and ChiNext indices fell [2] - The trading volume in the Shanghai and Shenzhen markets exceeded 2 trillion yuan for the first time this year, marking the seventh consecutive trading day of such volume [2] Sector Performance - Securities stocks collectively faced a pullback, with notable declines including Changcheng Securities down over 6% and Hato Securities down over 5% [2][3] - Several high-priced stocks hit the daily limit down, including Lianhuan Pharmaceutical and Zhongdian Xindong, with others like Shunlian Bio and Sainuo Medical dropping over 8% [4] Banking Sector - In contrast, bank stocks showed strength in the afternoon, with Agricultural Bank of China and Postal Savings Bank reaching new historical highs during the session [2] Hong Kong Market - The Hang Seng Index fell over 0.5%, and the Hang Seng Tech Index dropped more than 1% [6] - AAC Technologies Holdings (02018.HK) saw a rapid decline of over 14% following the release of its interim results, despite reporting a revenue of 13.32 billion yuan, a year-on-year increase of 18.4% [6][8] Company Performance - AAC Technologies reported a gross margin of 20.7%, down 0.8 percentage points year-on-year, attributed to changes in product mix, while net profit attributable to shareholders increased by 63.1% to 876 million yuan due to improved profitability in optical business and rapid growth in precision structural components [8] - CICC noted that the overall valuation level of A-shares remains reasonable, but the rapid increase in trading volume may lead to short-term volatility [8]

Group 1 - A-share market experienced a decline in high-performing stocks in the afternoon session, with several companies hitting the daily limit down [1] - Notable companies that faced significant drops include Lianhuan Pharmaceutical, Zhongdian Xindong, Feilong Co., Jintian Co., which all hit the limit down, while Shenlian Biological, Sainuo Medical, Jimin Health, Wolong Electric Drive, Chuanrun Co., Hanzhong Precision, and Guangsheng Tang all fell over 8% [1]

Group 1 - A-share market experienced a decline in high-performing stocks in the afternoon session, with companies such as Lianhuan Pharmaceutical, Zhongdian Xilong, Feilong Co., and Jintian Co. hitting the daily limit down [1] - Other companies like Shenlian Bio, Sainuo Medical, Jimin Health, Wolong Electric Drive, Chuanrun Co., Hanzhong Precision, and Guangsheng Tang saw declines exceeding 8% [1] Group 2 - MACD golden cross signal has formed, indicating a positive trend for certain stocks [2]